Basilio Hernández Email & Phone Number

San Cugat Del Vallés, Cataluña / Catalunya, España

Lead the medical strategy to launch AMBAR, the Grifols Alzheimer’s disease therapy on plasma exchange plus albumin. KOLs management, advisory boards, communication plan, neurological societies engagement, RWE studies, observational studies, medical education

Barcelona, Cataluña, España

• Leading NS Medical Team (4 Medical Advisors, 1 CRMA, 2 MSLs Heads, 12 MSLs) in the areas of migraine (Aimovig®, erenumab) and Multiple Sclerosis (Gilenya®, fingolimod, siponimod and ofatumumab)KEY ACHIEVEMENT
• Spanish launch of Aimovig® (Monoclonal anti-CGRP drug for migraine)

Madrid Y Alrededores, España

• Management of the Medical Affairs Team (4 Medical Advisors, 4 MSLs, Pharmacovigilance and Regulatory) which deals with the medical activities related to Parkinson’s disease, Epilepsy, Cardiovascular and Respiratory..
• Launch of respiratory licensed drugs.

Porto Area, Portugal

• Management of the Global Medical Parkinson’s disease -PD- team (Global Medical Associate and MSLs teams in DE and UK). Medical responsible activities related to PD. Providing medical strategy to the Global PD group.
• European ONgentys launch: DE & UK (2016); SP & IT (2017).
• Setting-up OPC Steering Group (Network of PD KOL´s)
• Management OPC International Symposia (MDS, 2015; EAN, 2016&17)

Amsterdam, Países Bajos

• Scientific coordination of European activities and events related to Parkinson’s disease (rasagiline), Huntington’s (pridopidine) and migraine (CGRP antibody) Developing clinical relationships with EU KOLs. Providing.
• Medical coordination of rasagiline Symposia at WCN, Vienna, 2013; WFN, Geneva, 2013; ENS-EFNS, Istanbul, 2014; MDS, Stockholm, 2014
• Setting-up of the Huntington’s and Migraine EU Medical Task Force

Barcelona

• Medical management and support of region IBERIA (Spain and Portugal). Management of the medical team: one medical advisor and 3 MSLs. Scientific and projects support: symposiums, advisory boards, advocacy and.
• Pre-laucnh of the first meningitis-B vaccine (Bexsero)

• Medical responsibility for marketed neurological drugs (rivastigmine: Alzheimer’s and entacapone; Parkinson’s disease) and early development of pipeline products (ATI355, AFQ056, CAD106). Region Europe Medical Lead for.
• Medical management of the Stalevo and Exelon Patch launch in Spain.
• 1st (B. Aires) and 2nd (Cuzco) Latin-American Congress on Parkinson’s

• Responsible for Stilnox® and Tranxilium®. Medical support and training to MK and sales reps. Post-Marketing Surveys implementation and communications plans. Medical Product Plan (Strategy and medical activities)KEY.
• Coordination of the firts Spanish Consensus on drug treatment, definition and diagnosis of insomnia published at Clin Drug Invest 2003

• Working on the copany when it was Grupo Vita, I was in charge of medical support of 13 marketed products (including nimodipine, ranitidine, famotidine, ondansetron, calcium and vitamin D…) Support to MK team. Sales.
• Medical management Ostine® launch (Calcium and vitamin D)

Gavà, Cataluña / Catalunya, España

• High-quality sportsmen medical checking. Implementation of qualified checking levels. Associate Teacher at the Sports Medicine School (Universidad Central de Barcelona)KEY ACHIEVEMENT:
• Development of an innovative Sports Medicine Clinical software

Baix Llobregat, Catalunya, Spain

Family doctor providing care at several surgery/health centers, coordinating and scheduling emergency teams

Medical Degree (Md), Medicine

Corporate Master In Business Administration

Online Course, Basic Marketing

Posgrado, Sport Medicine

Course, Pharmaceutical Industry Medical Marketing And Outsourcing On Clinical Investigation